Robuta

https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2012/12/21/16/45/Periprocedural-Heparin-Bridging-in-Patients-Receiving-Vitamin-K
vitamin k antagonistsheparinbridgingpatientsreceiving
https://pubmed.ncbi.nlm.nih.gov/26493768/
Real-life rates for bleeding, arterial thrombotic events, ACS and deaths in AF patients treated with VKA were similar to those observed in clinical trials.
population databasevitamin kstudyoutcomesassociated
https://www.rti.org/publication/dabigatran-versus-vitamin-k-antagonists-atrial-fibrillation-clinical-practice-final-outcomes-phase-i
BACKGROUND: Prospectively collected, routine clinical practice-based data on antithrombotic therapy in non-valvular atrial fibrillation (AF) patients are...
vitamin k antagonistsatrial fibrillationdabigatranversusclinical
https://pubmed.ncbi.nlm.nih.gov/34767564/
Apixaban was a dominant treatment strategy than VKA from both the Spanish payer's and societal perspectives, regardless of treatment strategy considered.
cost effectiveness analysisvitamin k antagonistsapixabanversus